Cloudbreak®
Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple potent drugs to a human antibody fragment. These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system.
DFCs have the potential to become novel treatments for cancer. Discovery efforts are ongoing.
Subscribe here for updates.
